This study aimed to evaluate the feasibility and safety, and to observe early efficacy signals of the focused ultrasound mediated drug delivery system combined with SonoVue® in patients with HER2-positive breast cancer receiving neoadjuvant therapy by comparing its pathological complete response (pCR) rate with a matched historical cohort of HER2-positive breast cancer patients treated at our center.
Female patients aged 18-70 years.
Histologically confirmed HER2 positive breast cancer, with indication for neoadjuvant chemotherapy, and scheduled to receive the T(P)CbHP neoadjuvant regimen.
TNM stage T2N0-2M0.
Adequate bone marrow reserve (ANC >1.5×10⁹/L, platelets >100×10⁹/L).
Prior history of radiotherapy or chemotherapy.
Pregnant or lactating patients.
Presence of distant metastasis.
Bilateral invasive breast cancer.